Tag Archives: GSK

Best Safest Stocks To Invest In Right Now

ArcelorMittal (NYSE:MT) has recovered remarkably on the market despite announcing mixed results on November 8. Though the company was able to beat the bottom line estimate comfortably, it had missed Wall Street’s revenue estimate by a huge figure of $670 million due to lower sales. At the same time, ArcelorMittal warned that steel prices in the U.S. could take a beating on account of lower demand, while higher coking coal costs will reduce profitability.

But, on the same day, after it was confirmed that the next government in the U.S. will be led by Donald Trump, ArcelorMittal shares started making a comeback. In fact, the stock has erased all the losses that it saw after a largely negative quarterly report, which is not surprising if we consider the possible improvements in the steel market in the U.S. under a Trump presidency. Let’s take a look.

ArcelorMittal shouldn’t be afraid of lower pricing

Under a Trump presidency, steel companies in the U.S. are anticipated to benefit from two factors – higher demand for steel due to aggressive infrastructure investments and less competition from cheap Chinese steel. As far as the first factor is concerned, Donald Trump has pledged to invest up to $1 trillion in infrastructure over the next decade, driven by an increase in public-private partnerships to speed up development.

Best Safest Stocks To Invest In Right Now: CVR Partners LP(UAN)

Advisors’ Opinion:

  • [By Cameron Swinehart]

    Going forward I will be looking to add investments on my watchlist and trim other positions. It will be interesting to see how an overweight commodity portfolio will perform relative to the rest of the market.

     Cost Basis# SharesCurrent Price% of PortfolioCurrent ValueReturnMetal/Miners      Sprott Physical Gold Trust (PHYS)$12.4985$11.043.75%$938.40-13.13%Sprott Physical Silver Trust (PSLV)$7.95125$8.744.37%$1,092.509.04%FreePort-McMoran (FCX)$31.6731$33.874.20%$1,049.976.50%Ishares MSCI Global Gold Miners ETF (RING)$13.0695$10.644.04%$1,010.80-22.74%Energy      Statoil ASA(STO)$21.7940$22.683.63%$907.203.92%Vanguard Natural Resources LLC (VNR)$27.5636$27.874.01%$1,003.321.11%ConocoPhillips (COP)$63.6822.43$71.006.37%$1,592.5310.31%Agriculture      CVR Partner LP (UAN)$26.3630.9$18.932.34%$584.94-39.25%Adecoagro$6.78125$7.443.72%$930.008.87%Archer-Daniels Midland (ADM)$34.8030$37.244.47%$1,117.206.55%Mixed Commodity      Powershares DB Commodity Index (DBC)$26.3540$25.954.15%$1,038.00-1.54%Sprott Resource Corp$3.34400$2.714.34%$1,084.00-23.25%    Total % of portfolio49.40%               Cost Basis12,666.00      Current Value12,348.86      Return-2.50%  Source: Investing For The Future Surge In Commodity Prices

    Disclosure: I am long ADM, FCX, UAN, AGRO, RING, VNR, SCPZF.PK, COP, DBC, PHYS, PSLV. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More…)

  • [By Robert Rapier]

    Enter CVR Partners LP (NYSE: UAN), the only company in the US to produce fertilizer from petroleum coke (petcoke). Petcoke is a byproduct of petroleum refining, and prices are usually set off coal prices, since these two products compete in the same niche. Thus the same dynamics that currently threaten the distributions of Rentech Nitrogen Partners and Terra Nitrogen Company play in CVR Partners’ favor.

  • [By Lisa Levin]

    In trading on Tuesday, basic materials shares declined by 1.82 percent. Meanwhile, top losers in the sector included CVR Partners LP (NYSE: UAN), down 10 percent, and Resolute Forest Products Inc (NYSE: RFP), down 9 percent.

Best Safest Stocks To Invest In Right Now: GlaxoSmithKline PLC(GSK)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Two of our top holdings, GlaxoSmithKline (GSK) and Merck (MRK) have seen substantial improvement in earnings as new drugs start to build market share. Glaxo and Merck offer dividend yields of 4.71% and 3.08%, respectively.

  • [By Paul Ausick]

    GlaxoSmithKline plc (NYSE: GSK) dropped about 1% Wednesday to post a new 52-week low of $34.52 after closing at $34.86 on Tuesday. The stock’s 52-week high is $44.54. Volume of around 4.8 million was about equal to the daily average. The company’s HIV drug is being challenged by a potentially better drug from competitor Gilead Sciences.

  • [By Todd Campbell]

    Also, like in hepatitis C, competitors are attempting to win away market share. For example,ViiV Healthcare, a joint venture spearheaded by GlaxoSmithKline(NYSE:GSK), is actively pursuing new HIV therapies that could make it more difficult for Gilead Sciences to maintain its market share dominance. In December, ViiV announced that a single tablet, two-drug combination that includes Johnson & Johnson’s Edurant met its primary endpoint in phase 3 studies. A filing for FDA approval is slated for this year.

  • [By Keith Speights]

    Gilead’s primary rival in the HIV market is Viiv Healthcare, which is majority-owned byGlaxoSmithKline (NYSE:GSK).The company recently announced positive results from a late-stage clinical study of its HIV drug Tivicay combined with Johnson & Johnson’s Edurant.

Best Safest Stocks To Invest In Right Now: Cummins Inc.(CMI)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    There are lots of stories like that out there these days. People were perplexed about the Illinois Tool Works (ITW) and Cummins Engine (CMI) and Caterpillar (CAT) quarters, but they turned out to be classic buying opportunities after years of being sell opportunities if the stocks had run. I can’t explain to you how amazing that is. Here are three stocks that have spent months and months in purgatory when they have missed or guided down or slashed forecasts. Now they are up gigantically.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Friday was Cummins Inc. (NYSE: CMI) which traded down about 5% at $159.44. The stocks 52-week range is $134.06 to $181.79. Volume was over 3.5 million versus the daily average of 1.2 million shares.

  • [By Reuben Gregg Brewer]

    Ever walk past a construction site? It’s hard not to be enthralled by all the heavy construction machinery moving things around. With the world’s developing economies still building at a relatively fast pace and developing economies, like the United States, in desperate need of upgrading their aging infrastructure, the companies behind that construction machinery could be just as exciting as a construction site in the years ahead. Which is why Caterpillar Inc. (NYSE:CAT), Cummins Inc. (NYSE:CMI), and Terex Corporation (NYSE:TEX) are three of the top construction machinery stocks to look at right now.

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Salesforce.com (CRM) , Paccar (PCAR) , Cummins (CMI) , ConocoPhillips (COP) , Adobe Systems (ADBE) , Annaly Capital (NLY) and Hewlett Packard Enterprise (HPE) .

  • [By Reuben Gregg Brewer]

    Making mining equipment has been a horrible business over the last few years. The industry has been hard-hit by the spending cutbacks at mine sites around the world. For example, BHP Billiton Limited trimmed its capital exploration expenditures by roughly 70% between fiscal 2013 and 2016. No wonder Caterpillar Inc. (NYSE:CAT), Komatsu Ltd. (NASDAQOTH:KMTUY), and Cummins Inc. (NYSE:CMI) have been hurting. Only that looks like it’s starting to change, which means this trio could be at the top of a list of mining equipment companies to buy in 2017.

Best Safest Stocks To Invest In Right Now: E*TRADE Financial Corporation(ETFC)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    E*Trade Financial Corp. (NASDAQ: ETFC) was up another 1.6% at $32.97. Ithas a total market cap of $9 billion, and over the past five trading days the stock has gained 17%. Shares of Morgan Stanley (NYSE: MS) were last seen at $39.09, up 17% in the past fivetrading days. The market cap is$74.7 billion.

  • [By WWW.THESTREET.COM]

    Franklin Resources (BEN) : “I’d rather see you in Morgan Stanley (MS) or E*TRADE Financial (ETFC) .”

    Kinder Morgan (KMI) : “They are OK now, but there are better ones.”

  • [By Dan Caplinger]

    Meanwhile, E*Trade (NASDAQ:ETFC) decided to split the difference. Effective March 13, E*Trade’s commission structure will get split in two. Base rate customers will see their commissions fall from $9.99 to $6.95 per trade, matching TD Ameritrade. However, E*Trade created a new structure for active traders, defined as those who execute 30 or more trades every three months. For those customers, E*Trade will have $4.95 per trade commissions, and options charges will fall by a third, to $0.50 per contract. CEO Karl Roessner said that although “an exceptional customer experience is far more important to traders and investors than price, with our new commission structure, we are able to reward our most active equity and derivative traders and investors.”

  • [By Chris Neiger]

    This article will walk your through all the steps for setting up an individual E*TRADE (NASDAQ:ETFC) brokerage account, which should only take about five to 10 minutes to complete. If you want to compare offers from other brokers, or view their features, check out ourbroker comparison page.

Best Safest Stocks To Invest In Right Now: Bruker Corporation(BRKR)

Advisors’ Opinion:

  • [By Javier Hasse]

    Yet another stock experiencing a correction after the bell was Bruker Corporation (NASDAQ: BRKR), which lost 2.75 percent in after-hours, after having gained 4.5 percent during the day.

Best Safest Stocks To Invest In Right Now: Natural Grocers by Vitamin Cottage, Inc.(NGVC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Natural Grocers by Vitamin Cottage Inc (NYSE: NGVC) was down, falling around 33 percent to $5.70 as the company posted downbeat quarterly results and lowered its FY17 earnings guidance.

  • [By Peter Graham]

    A long term performance chart for Whole Foods Market shows along with mid cap peerSprouts Farmers Market Inc (NASDAQ: SFM) and Natural Grocers by Vitamin Cottage (NYSE: NGVC) appearing to all be in downtrends that may or may not have leveled off:

  • [By Peter Graham]

    A long term performance chart for Whole Foods Market shows along with mid cap peerSprouts Farmers Market Inc (NASDAQ: SFM) and Natural Grocers by Vitamin Cottage (NYSE: NGVC) largely drifting lower with two price spikes:

Week In Review: China Life Science Starts 2018 With $2 Billion Week

Perennial Real Estate Holdings (SGX: 40S), a Singapore company, announced a $1.2 billion joint venture that will acquire and develop healthcare centers in China. It plans to concentrate on integrated mixed-use developments, centered around healthcare, that are connected to China high speed railway stations. Perennial is already building two such properties, one in Chengdu and the other in Xi’an. Its major partner in the JV will be Shun Tak Holdings (HK: 242), a Hong Kong conglomerate. Perennial contributed $225 million to the first close of the JV, which is $500 million.

Jiangsu Hengrui Medicine (SHA: 600276) out-licensed ex-China rights for a novel JAK inhibitor to Arcutis Pharma, a California dermatology company, in a deal worth up to $233 million, plus royalties. Arcutis will have rights to SHR0302 to treat dermatology disorders in the US, Europe and Japan. Hengrui is testing SHR0302 in a China Phase II trial for rheumatoid arthritis, though its agreement with Arcutis includes only topical use of the drug for dermatology diseases.

SomaLogic of Boulder, Colorado capped its $200 million funding round, anchored by China’s iCarbonX and joined by Nan Fung Life Sciences and Madryn Asset Management. SomaLogic measures the levels of human proteins in an individual as a tool for managing their health and wellness. The company’s SOMAscan technology, which currently measures 5,000 proteins per sample, has analyzed more than 150,000 samples across more than 50 diseases or conditions. It plans to complete another 1 million samples by the end of 2020.

Aslan Pharma (TT: 6497) (OTC:APRTF) of Singapore acquired global rights to varlitinib, its lead candidate aimed at several solid tumor cancers, from Array BioPharma (NASDAQ:ARRY) in a $129 million agreement. In 2011, Aslan originally acquired rights to varlitinib through proof-of-concept stage. At that point, Aslan planned to partner the drug to a third party, with Aslan and Array splitting the proceeds. Now, Aslan will own full commercialization rights to varlitinib with two payments of $12 million, plus $105 million of milestones and tiered low double-digit royalties on varlitinib sales.

Sansure Biotech of Changsha, a molecular diagnostics company, raised $77 million in a funding round led by Lilly Asia Ventures and Highlight Capital with participation from June Capital. Sansure provides innovative molecular diagnosis and genetic testing kits and tools to diagnostic labs and researchers. It makes nucleic acid extraction kits, real time polymerase chain reaction (PCR) diagnostic and research kits and fluorescence systems. Sansure claims to be the second-largest China company in its market niche.

KBP Biosciences, a Jinan clinical-stage pharma, closed a $76 million Series A financing to support its pipeline and open a global Philadelphia headquarters. The company will continue to operate its Jinan facility. KPB focuses on re-purposing approved medications with well-understood mechanisms to treat unmet needs. The company was founded by serial entrepreneur Dr. Zhen Hua Huang, who previously owned a China generics company. As part of the new funding, KBP hired Brian McVeigh, a GSK (NYSE:GSK) veteran, as CEO.

Beijing’s Genetron Health, a precision medicine oncology company, raised over $61 million in a Series C round led by Zhongjin Kangrui Medical Industrial Fund. Founded in 2013, Genetron offers molecular clinical services and professional cancer genetic risk assessment, covering full-cycle cancer clinical treatment. The company has R&D centers in North Carolina and Beijing, plus clinical medical testing centers in Beijing, Shanghai and Hangzhou.

Zhejiang DTRM Biopharma announced a $60 million Series A round that will support clinical trials of its lead cancer candidate, a Bruton’s tyrosine kinase (BTK) inhibitor. The candidate is currently in US and China Phase I trials for B cell lymphoma and chronic lymphocytic leukemia. DTRM was established in 2011 by He Wei, PhD, a returnee, and Zhejiang Hisun Pharma (SHA: 600267). The company is testing its BTK-inhibitor as a monotherapy and in combination with other drugs.

ApolloBio (NEEQ: 430187), a Beijing company focused on cancer, has amended its year-old deal to acquire China rights to Inovio’s (NYSEMKT:INO) DNA immunotherapy aimed at pre-cancers caused by human papillomavirus (HPV). Under the new terms, ApolloBio will pay $23 million upfront (previously: $15 million) and $20 million (unchanged) in milestones, plus double-digit tiered royalties on sales. Also, ApolloBio will not purchase $35 million in Inovio stock. As before, the agreement gives ApolloBio the right to develop and commercialize VGX-3100 in greater China.

CMAB Biopharma completed a $38 million Series A funding for its biologic CRO/CMO operations in Suzhou BioBay Park. The company offers process development and manufacturing services for biologic products. The funding was led by C-Bridge Capital, a healthcare PE investor involved mainly with China life science companies, along with BioBAY, a healthcare park, and joined by I-Bridge Capital and Qianhai FoF fund. I-Bridge is the early stage investor of the C-Bridge Group. CMAB intends to serve China and global biotech clients.

Miracor Medical, an Austrian medical device company, closed a $30 million D funding round, led by Ming Capital of Shenzhen. Miracor is developing an innovative device aimed at limiting damage following a coronary blockage. The company said it would use the new funds to conduct a European test of its device, the PcCSO Impulse System, and begin work for regulatory approval in the US. Because several of the round’s participants are Belgian state investors, Miracor will move to Belgium as part of the funding.

Laviana Pharma (NEEQ: 838853), a CRO/CMO with subsidiaries in Beijing and Tianjin, plus a business office in the US, closed a $15 million Series B funding led by Shenzhen Huayi Capital. Founded in 2005 by returnees, Laviana provides outsourced small molecule process and manufacturing services to pharmaceutical companies. In 2016, Laviana listed shares on China’s NEEQ, an OTC exchange that lists shares without raising any capital for companies.

Genostics, a Hong Kong diagnostics company, will acquire China rights to Oncimmune’s blood-based cancer testing platform in return for a $13.5 million investment into the UK-based company’s shares. Initially, Genostics will bring Oncimmune’s EarlyCDT-Lung to China. The product is an early, blood-based lung cancer screening test for use in smokers who have not shown symptoms of the disease. Oncimmune will receive a royalty of 8% on the gross revenue, with minimum royalty payments of $21 million over the first six years and $7 million per year thereafter.

Illumina (NASDAQ:ILMN) will collaborate with China’s KingMed Diagnostics (SHA: 603882) to develop ready-to-use in-vitro diagnostic (IVD) assays for molecular oncology and hereditary cancer testing in China. The parties will combine Illumina’s bench-top MiniSeq NGS sequencer with KingMed’s testing components, which include library preparation kits and analysis software. In China, KingMed supplies testing products to 21,000 medical institutions and operates 37 independent testing labs.

Xinogen (Hong Kong) Pharma will collaborate with Montreal’s Angiochem to develop Angiochem’s paclitaxel-Angiopep-2 conjugate in China. ANG1005 is aimed at treating leptomeningeal carcinomatosis, a neurological metastasis, from breast cancer. Xinogen is a subsidiary of Beijing Shenogen Pharma, a company that is developing small molecule and biologic treatments for cancer. Xinogen, which acquired China rights to develop and commercialize ANG1005, will make upfront and milestone payments and also pay royalties on sales, though specific details were not disclosed.

Disclosure: None

SeekingAlphaAbout this article:ExpandTagged: Investing Ideas, Quick Picks & ListsWant to share your opinion on this article? Add a comment.Disagree with this article? Submit your own.To report a factual error in this article, click here

recommended stock buys

By Richard Watts, Next Avenue Contributor 

(This provocative article is adapted from the new book, Entitlemania, by Richard Watts.)

Somewhere in our DNA as parents, we believe it is an act of love, generosity, or for some, contrition, to leave our children an inheritance after we die. And the more money we leave, we think, the better! But despite the wisdom and warnings of historical philosophy, religious texts and psychology, we refuse to heed the whispers and acquiesce to our irrefutable belief that our children will both benefit from, and appreciate our gift.

Credit: Shutterstock

Beware . . . For everything you give your child, you take something away.

Yet parents often adjust their retirement budget for food, shelter, travel and recreation so they can “leave a little something” to their children. And many, modestly surviving on Social Security, even feel a twinge of guilt if they exit the planet saddling their children with funeral and burial expenses.

recommended stock buys: Duke Energy Corporation(DUK)

Advisors’ Opinion:

  • [By WWW.KIPLINGER.COM]

    Duke Energy Corp. (DUK), the largest generator of electricity in the nation, is awfully steady.

    DUK has more than 7.4 million customers located in hotbeds of growth, and it boasts a generating capacity of 52,697 megawatts. The firm also provides natural gas distribution in many of its main service areas, so Duke is a double threat in that way. Cold winter? Nat gas provides more oomph. Hot summer? Electricity demand spikes.

recommended stock buys: U.S. Physical Therapy, Inc.(USPH)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, healthcare shares fell 0.73 percent. Meanwhile, top losers in the sector included U.S. Physical Therapy, Inc. (NYSE: USPH), down 7 percent, and Fluidigm Corporation (NASDAQ: FLDM), down 7 percent.

recommended stock buys: Zion Oil & Gas Inc(ZN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Zion Oil & Gas, Inc. (NASDAQ: ZN) got a boost, shooting up 47 percent to $6.21.

    Spark Energy Inc (NASDAQ: SPKE) shares were also up, gaining 10 percent to $19.10. Guggenheim upgraded Spark Energy from Neutral to Buy.

  • [By Lisa Levin]

    In trading on Wednesday, energy shares fell by 0.76 percent. Meanwhile, top losers in the sector included Whiting Petroleum Corp (NYSE: WLL), down 6 percent, and Zion Oil & Gas, Inc. (NASDAQ: ZN) down 7 percent.

  • [By Lisa Levin]

    Shares of Zion Oil & Gas, Inc. (NASDAQ: ZN) got a boost, shooting up 20 percent to $5.07.

    Spark Energy Inc (NASDAQ: SPKE) shares were also up, gaining 12 percent to $19.40. Guggenheim upgraded Spark Energy from Neutral to Buy.

recommended stock buys: GlaxoSmithKline PLC(GSK)

Advisors’ Opinion:

  • [By Keith Speights]

    Gilead’s primary rival in the HIV market is Viiv Healthcare, which is majority-owned byGlaxoSmithKline (NYSE:GSK).The company recently announced positive results from a late-stage clinical study of its HIV drug Tivicay combined with Johnson & Johnson’s Edurant.

  • [By WWW.MONEYSHOW.COM]

    Two of our top holdings, GlaxoSmithKline (GSK) and Merck (MRK) have seen substantial improvement in earnings as new drugs start to build market share. Glaxo and Merck offer dividend yields of 4.71% and 3.08%, respectively.

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on GlaxoSmithKline (GSK) , Chubb (CB) , XPO Logistics (XPO) , FedEx (FDX) and Nordson (NDSN) .

    Cramer was bearish on Prudential (PRU) , Advanced Semiconductor Engineering (ASX) and ZTO Express (ZTO) .

  • [By Sean Williams]

    Third, in late March, Mylan announced that the Food and Drug Administration had rejected its application to market a generic version of GlaxoSmithKline’s (NYSE:GSK) blockbuster asthma and COPD inhalable drug, Advair. GlaxoSmithKline’s Advair lost patent protection more than six years ago, but only within the past couple of years did the FDA lay out a course for generic drug producers to follow in order to get a generic version of the drug approved. Meanwhile, Glaxo still enjoys blockbuster sales of Advair as generic versions of the drug have yet to hit the market.

  • [By WWW.MONEYSHOW.COM]

    Donald Trump understands how regulation harms both businesses and consumers, discouraging innovation and raising costs. In a recent news conference, he pledged to “cut regulations by 75%, maybe more.”  This is good news indeed for drug companies like GlaxoSmithKline (GSK).

recommended stock buys: CA Inc.(CA)

Advisors’ Opinion:

  • [By ]

    Last but not least, the conversion and consolidation of the American healthcare colossus will be a bonanza for tech companies engaged in networking, software, and the cloud. Those best suited to handle the task are the usual suspects: Cisco Systems (Nasdaq: CSCO), Microsoft (Nasdaq: MSFT), IBM (NYSE: IBM), CA Technologies (Nasdaq: CA), Oracle (Nasdaq: ORCL), and Hewlett Packard (NYSE: HPE).

  • [By Lisa Levin]

    In trading on Thursday, technology shares fell 1.57 percent. Meanwhile, top losers in the sector included CA, Inc. (NASDAQ: CA), down 10 percent, and DST Systems, Inc. (NYSE: DST), down 10 percent.

  • [By Laurie Kulikowski]

    We rate CA INC as a Hold with a ratings score of C+. The primary factors that have impacted our rating are mixed – some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company’s strengths can be seen in multiple areas, such as its attractive valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and a generally disappointing performance in the stock itself. 

  • [By Laurie Kulikowski]

    Regardless of the drop in revenue, the company managed to outperform against the industry average of 15.5%. Since the same quarter one year prior, revenues slightly dropped by 6.8%. Weakness in the company’s revenue seems to have hurt the bottom line, decreasing earnings per share.

    Net operating cash flow has decreased to $45.00 million or 31.81% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm’s growth is significantly lower.

     

  • [By Laurie Kulikowski]

    The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and greatly underperformed compared to the Software industry average. The net income has significantly decreased by 32.0% when compared to the same quarter one year ago, falling from $256.00 million to $174.00 million.

     

  • [By Laurie Kulikowski]

    The current dividend yield for CA is 3.55%, well above the 2.07% for the S&P 500. We believe the dividend is safe as improvements in marketing and sales should help return the top line to growth in the middle of calendar 2016, while still seeing modest margin expansion. 

invest definition

Source: Stock Photo

The first thing to understand about Energen (NYSE:EGN) it has the capability and will to increase production steadily over the next three years, even if oil were to remain at about $50 per barrel. As it stands, the company believes should be able to double output by the end of 2019.

By the end of 2017 the company guides for production jump to about 65.7 MBOE per day, and by 2019 to reach 100,000 BOE per day. In 4Q16, production was at 53.5 MBOE per day.

When considering the implications of the recent well completion of EOG Resources (NYSE:EOG), suggesting resource and reserves in the play could be much higher than believed – of which Energen has a lot of exposure – the long-term outlook for the company appears to be even better than it already was.

invest definition: Alexco Resource Corp(AXU)

Advisors’ Opinion:

  • [By Cameron Saucier]

    Alexco Resource (NYSEMKT: AXU) operates in two segments: an environmental services business and a mining company. Its mining segment explores developments in Canada, while its environmental segment provides consulting and project management services in the United States and Canada. AXU is up over 400% YTD. The stock has been steadily rising since January. It isn’t clear what’s driving AXU upwards, other than general investor speculation. The stock is trading at $1.72 per share as of Monday intraday.

invest definition: OSI Systems, Inc.(OSIS)

Advisors’ Opinion:

  • [By Jim Robertson]

    Small cap homeland security and screening stocks like FLIR Systems (NASDAQ: FLIR), OSI Systems (NASDAQ: OSIS),Varex Imaging Corp (NASDAQ: VREX) and Patriot One Technologies (OTCQB: PTOTF) stand to benefit fromTrumps focus on border andinternal security in general. Heres what you need to know about all four:

  • [By Paul Ausick]

    OSI Systems Inc. (NASDAQ: OSIS) dropped 36% Wednesday to post a new 52-week low of $53.80 after closing at $84.07 on Tuesday. The 52-week high is $96.64. Volume was around 9 million, around 6 times the daily average of about 155,000. Short seller Muddy Waters called OSI “rotten to the core” in a new report this morning.

  • [By Bryan Murphy]

    Look out OSI Systems, Inc. (NASDAQ:OSIS), and step aside American Science & Engineering, Inc. (NASDAQ:ASEI). You may be the key names in weapons detection and security screening right now, but an up-and-comer called Patriot One Technologies Inc. (CVE:PAT, OTCMKTS:PTOTF) is about to unleash a rival product that turns heads, and steals your customers.

    Weapons detection tools in a world that’s always got terrorism threats lurking around every corner are no laughing matter, though were it any other subject, the results would be laughable. See, as advanced as the x-ray and screening products made by American Science & Engineering and OSI Systems may be, they just don’t work well enough.

    Case in point: A recent internal investigation performed by the Transportation Security Administration (TSA) found that undercover investigators were able to smuggle fake explosives and weapons through checkpoints in 95% of trials, which they conducted at dozens of America’s busiest airports. What’s the point?

    For the past several years Patriot One Technologies has been working on a technology, called the CMR1000, that changes everything.

    The CMR1000 (‘CMR’ is an short for Cognitive Microwave Radar) is an amazing device. It works not unlike a X-ray machine at an airport, but also not unlike a more conventional metal detector you might find at an airport or at the entryway to a building. In all regards though, it’s better than both. By using high-frequency microwaves that are harmless to humans, the CMR1000 can even pinpoint exactly what kind of metallic weapon it is… a semi-automatic pistol versus a revolver, or a machete versus a pocket knife. Most important, the CMR1000 boasts a (very) high detection-accuracy rate of 93%.

    And it’s almost ready… ready enough to officially unveil this April at the ISC West (International Security Conference) in Las Vegas, and immediately begin taking orders for initial deliveries around the middle of

  • [By Bryan Murphy]

    If shareholders of OSI Systems, Inc. (NASDAQ:OSIS) and American Science & Engineering, Inc. (NASDAQ:ASEI) — makers of weapons detection systems — are getting a little nervous, that’s understandable. Never has either company’s share of the market been so threatened. Indeed, an up-and-coming company called Patriot One Technologies Inc. (CVE:PAT, OTCMKTS:PTOTF) fired another volley at American Science & Engineering and OSI Systems, announcing yet-another institution had asked for a real-life demonstration (on their premises) of the brand-new kind of anti-terrorism technology that Patriot One’s been developing for years.

    The CMR1000 (‘CMR’ is an short for Cognitive Microwave Radar) is nothing less than incredible. It works not unlike a X-ray machine at an airport, but also not unlike a more conventional metal detector you might find at an airport or at the entryway to a building. In all regards though, it’s better than both. By using high-frequency microwaves that are harmless to humans, the CMR1000 can even pinpoint exactly what kind of metallic weapon it is… a semi-automatic pistol versus a revolver, or a machete versus a pocket knife.

    This capability overcomes the key shortcoming of most threat-detection apparatus in use today…

    … which doesn’t work very well, by the way. A recent internal investigation performed by the Transportation Security Administration (TSA) found that undercover investigators were able to smuggle fake explosives and weapons through checkpoints in 95% of trials, which they conducted at dozens of America’s busiest airports.

    Patriot One Technologies is mostly excited about the launch of the CMR1000, however, because it’s not a mere threat-detection tool. Word will quickly spread that it’s a threat-deterrent tool; the easiest way combat violent action is not letting it happen in the first place, and the best way to do that to accurately find and accurately identify what the threat is, right down to

invest definition: (MALRF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].

invest definition: GenMark Diagnostics, Inc.(GNMK)

Advisors’ Opinion:

  • [By Lisa Levin]

    GenMark Diagnostics, Inc (NASDAQ: GNMK) shares shot up 20 percent to $10.54. Cowen & Co. upgraded GenMark Diagnostics from Market Perform to Outperform.

invest definition: Straight Path Communications Inc.(STRP)

Advisors’ Opinion:

  • [By Ashley Moore]

    We’ve compiled a list of the most heavily shorted stocks to show you which stocks have the most negative sentiment on the market…

    Company Name (Ticker)Short FloatShare PriceHanwha Q Cells Co. Ltd. (Nasdaq ADR: HQCL)98.52%$ 8.88Renren Inc. (NYSE: RENN)91.59%$ 8.53Weight Watchers International Inc. (NYSE: WTW)67.92%$12.57INSYS Therapeutics Inc. (Nasdaq: INSY)66.71%$10.74Twilio Inc. (NYSE: TWLO)66.34%$33.17Nutanix Inc. (Nasdaq: NTNX)65.65%$31.96Fitbit Inc. (NYSE: FIT)55.15%$ 6.06Weibo Corp. (Nasdaq ADR: WB)53.83%$55.26RPC Inc. (NYSE: RES)53.62%$21.19Straight Path Communications Inc. (NYSEMKT: STRP)49.27%$34.79Momo Inc. (Nasdaq ADR: MOMO)48.63%$26.80Seritage Growth Properties (NYSE: SRG)46.91%$44.87Lannett Company Inc. (NYSE: LCI)45.46%$23.00Gogo Inc. (Nasdaq: GOGO)43.98%$ 9.10Altisource Portfolio Solutions SA (Nasdaq: ASPS)42.78%$22.73Cheetah Mobile Inc. (NYSE ADR: CMCM)40.86%$10.00

    Some investors think the only way to profit from the stock market is to buy stocks and wait for the price to rise. However, these investors are missing out on the massive profit opportunity that comes from shorting stocks.

invest definition: GlaxoSmithKline PLC(GSK)

Advisors’ Opinion:

  • [By Sean Williams]

    Third, in late March, Mylan announced that the Food and Drug Administration had rejected its application to market a generic version of GlaxoSmithKline’s (NYSE:GSK) blockbuster asthma and COPD inhalable drug, Advair. GlaxoSmithKline’s Advair lost patent protection more than six years ago, but only within the past couple of years did the FDA lay out a course for generic drug producers to follow in order to get a generic version of the drug approved. Meanwhile, Glaxo still enjoys blockbuster sales of Advair as generic versions of the drug have yet to hit the market.

  • [By WWW.THESTREET.COM]

    Up first on our list of potentially toxic trades is $98 billion healthcare stock GlaxoSmithKline plc (GSK) . GSK has actually been an attractive name to own lately. Shares are up about 10.6% since bottoming back in December, besting the S&P over that timeframe. But if you own GlaxoSmithKline, now’s the time to start thinking about taking some of those recent gains off the table — shares are looking “toppy” this spring.

  • [By Keith Speights]

    There are several choices for investing in HIV drug stocks. Three of the best options for long-term investors are Gilead Sciences (NASDAQ:GILD), GlaxoSmithKline (NYSE:GSK), and Merck (NYSE:MRK). Here’s why these HIV drug stocks could be solid picks in 2017.

  • [By WWW.MONEYSHOW.COM]

    Two of our top holdings, GlaxoSmithKline (GSK) and Merck (MRK) have seen substantial improvement in earnings as new drugs start to build market share. Glaxo and Merck offer dividend yields of 4.71% and 3.08%, respectively.